Stockscreener 앱 받기
11.10
2.21%
0.24
시간 외 거래:
11.09
-0.010
-0.09%
전일 마감가:
$10.86
열려 있는:
$11.21
하루 거래량:
1.25M
Relative Volume:
0.75
시가총액:
$1.24B
수익:
-
순이익/손실:
$-129.47M
주가수익비율:
-7.3287
EPS:
-1.5146
순현금흐름:
$-114.08M
1주 성능:
-5.61%
1개월 성능:
-2.03%
6개월 성능:
+5.11%
1년 성능:
+48.59%
1일 변동 폭
$10.64
$11.36
1주일 범위
$10.64
$12.50
52주 변동 폭
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.10 | 1.22B | 0 | -129.47M | -114.08M | -1.5146 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Trading Down 6.7%Here's Why - MarketBeat
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - marketscreener.com
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat - GlobeNewswire
Experimental prostate cancer drug targets treatment resistance in lab tests - Stock Titan
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support - Sahm
ORIC PE Ratio & Valuation, Is ORIC Overvalued - Intellectia AI
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety ScrutinyWhat's Changed - Sahm
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Integral Health Asset Management LLC Cuts Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals, Inc.Common Stock (NQ: ORIC - The Chronicle-Journal
Oric Pharmaceuticals (ORIC) Sees Opportunity Amid Market Dynamics - GuruFocus
Oric Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
ORIC Pharmaceuticals Reiterates 'Buy' Rating with $25 Target by HC Wainwright | ORIC Stock News - GuruFocus
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns - Yahoo Finance
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Oric Pharmaceuticals celebrates Employee Appreciation Day with recognition initiatives - Traders Union
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 8.8%Here's Why - MarketBeat
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
ORIC Shares Drop Amid Market Withdrawal Concerns - GuruFocus
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat - TipRanks
March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC) - Meyka
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal By Investing.com - Investing.com India
ORIC Stock Recovers Amid Potential for Long-Term Success Despite Temporary Setback - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
Technical Reactions to ORIC Trends in Macro Strategies - Stock Traders Daily
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal - Investing.com UK
Jones Trading reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals Shares Drop Following Ipsen's Drug Withdrawal - GuruFocus
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright - Finviz
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating - TipRanks
After the Golden Cross, the technical perspective for Oric Pharmaceuticals, Inc. (ORIC) appears promising - Bitget
Is ORIC Pharmaceuticals Inc. stock positioned for digital transformation2026 Drop Watch & Reliable Breakout Stock Forecasts - Naître et grandir
Trend Report: What is ORIC Pharmaceuticals Inc.’s market positionGap Down & Entry Point Confirmation Signals - baoquankhu1.vn
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Earnings Update And New Shelf Registration - simplywall.st
Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks
JPMorgan Chase & Co. Has $14.74 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
History Review: What is ORIC Pharmaceuticals Incs market position2025 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP - MarketBeat
Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):